Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma

BACKGROUND: Relative effect of therapies indicated for the treatment of advanced renal cell carcinoma (aRCC) after failure of first line treatment is currently not known. The objective of the present study is to evaluate progression-free survival (PFS) and overall survival (OS) of cabozantinib compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Amzal, Billy, Fu, Shuai, Meng, Jie, Lister, Johanna, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590935/
https://www.ncbi.nlm.nih.gov/pubmed/28886175
http://dx.doi.org/10.1371/journal.pone.0184423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590935/
https://www.ncbi.nlm.nih.gov/pubmed/28886175
http://dx.doi.org/10.1371/journal.pone.0184423

Ejemplares similares